Emily Woodworth - 12 Feb 2026 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)

Reporting relationship: SVP, Global Controller and CAO
Issuer ticker: BSX
Reported as of: 12 Feb 2026
Net transaction value: -$17,937
SEC form: 4
Accepted by SEC: 17 Feb 2026, 19:07:55 UTC
Prior SEC filing: 05 Mar 2025
Next SEC filing: 18 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Susan Thompson, Attorney-in-Fact

Key filing fact

Emily Woodworth filed Form 4 for BOSTON SCIENTIFIC CORP (BSX) on 17 Feb 2026.

Key facts

This page summarizes Emily Woodworth's Form 4 filing for BOSTON SCIENTIFIC CORP (BSX).
5 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 17 Feb 2026, 19:07.

Change

Previous filing in this sequence was filed on 05 Mar 2025.
Current net transaction value: -$17,937.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002013518 Primary reporting owner

Woodworth Emily

Relationship: SVP, Global Controller and CAO
Address: 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH
Signature: /s/ Susan Thompson, Attorney-in-Fact
Signature date: 17 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BSX transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +481
Change %: +68%
Price: $0.000000
Shares after: 1,193
Date: 12 Feb 2026
Ownership: Direct
Footnotes: F1, F2

BSX transaction

Common Stock

Tax liability

Transaction value: $17,937
Shares: -242
Change %: -20%
Price: $74.12
Shares after: 951
Date: 12 Feb 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BSX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -481
Change %: -33%
Price: $0.000000
Shares after: 962
Date: 12 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 481
Exercise price
Footnotes: F1, F3

BSX transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +6,071
Change %
Price: $0.000000
Shares after: 6,071
Date: 12 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,071
Exercise price
Footnotes: F1, F4

BSX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +5,584
Change %
Price: $0.000000
Shares after: 5,584
Date: 12 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,584
Exercise price: $74.12
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

Footnote F2

Includes shares acquired on June 30, 2025 under the Company's Employee Stock Purchase Plan based upon the most current data available.

Footnote F3

Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant.

Footnote F4

Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant.

Footnote F5

Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant.